List of Excipients in Branded Drug TRUDHESA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Impel Pharmaceuticals LLC	TRUDHESA	dihydroergotamine mesylate	77530-725	ANHYDROUS DEXTROSE
Impel Pharmaceuticals LLC	TRUDHESA	dihydroergotamine mesylate	77530-725	CAFFEINE
Impel Pharmaceuticals LLC	TRUDHESA	dihydroergotamine mesylate	77530-725	CARBON DIOXIDE
Impel Pharmaceuticals LLC	TRUDHESA	dihydroergotamine mesylate	77530-725	WATER

Trudhesa Excipient Strategy and Commercial Opportunities

Last updated: August 21, 2026

Trudhesa is a dihydroergotamine mesylate nasal spray approved by the FDA for the acute treatment of migraine with or without aura in adults. Its formulation uses a conventional aqueous excipient system: phosphate buffers, citric acid, dextrose and water for injection. The primary commercial moat is the combination of formulation, nasal delivery performance, device design and manufacturing control rather than a novel excipient.

The strongest excipient opportunities are qualified-source expansion, preservative-free nasal products, stability-enhanced presentations, generic or 505(b)(2) reformulations, and platform licensing for other high-potency nasal drugs.

What excipients are used in Trudhesa?

Trudhesa contains dihydroergotamine mesylate at a delivered dose of 0.725 mg per spray. The FDA-approved inactive ingredients are citric acid monohydrate, dextrose anhydrous, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate and water for injection.[1]

Excipient	Primary function	Commercial relevance
Citric acid monohydrate	pH adjustment and buffering	Controls nasal tolerability, chemical stability and DHE solubility
Sodium phosphate dibasic anhydrous	Buffer component	Helps maintain formulation pH during shelf life
Sodium phosphate monobasic monohydrate	Buffer component	Works with dibasic phosphate to establish buffer capacity
Dextrose anhydrous	Tonicity adjustment and formulation stabilization	Influences comfort, osmolality and potentially spray performance
Water for injection	Vehicle	Requires high-purity pharmaceutical water and controlled microbial quality

The label does not identify a conventional antimicrobial preservative such as benzalkonium chloride, phenylephrine or chlorobutanol.[1] That preservative-free profile can support nasal tolerability and creates a potential differentiation point against multi-dose nasal products that rely on preservatives.

How does the Trudhesa formulation work?

The formulation is an aqueous buffered solution designed to deliver DHE through the nasal cavity using Impel NeuroPharma's Precision Olfactory Delivery, or POD, technology. The device directs the spray toward the upper nasal space rather than relying only on conventional anterior nasal deposition.[2]

The excipient system has four technical objectives:

1. Maintain DHE in a stable, soluble aqueous environment.
2. Control pH to limit irritation and chemical degradation.
3. Adjust tonicity for nasal comfort.
4. Preserve reproducible spray performance over the product's shelf life.

The excipients are individually conventional. The performance advantage comes from their concentration ranges, pH, interaction with DHE mesylate, container closure, dose metering and device-generated plume.

Why the buffer system matters

DHE is a potent ergot alkaloid with clinically important vasoconstrictive activity. Small changes in pH can affect ionization, solubility, chemical stability and nasal exposure. A generic manufacturer cannot treat the phosphate and citric acid system as interchangeable commodity ingredients without demonstrating equivalent product quality and clinical performance.

Key formulation controls include:

• pH and buffer capacity
• osmolality
• DHE assay and related substances
• extractables and leachables
• spray content uniformity
• droplet-size distribution
• plume geometry
• priming and re-priming performance
• microbial quality
• container closure integrity

What commercial opportunities exist for Trudhesa excipients?

The largest opportunities are in supply-chain resilience and formulation-enabled lifecycle management. No excipient in the product is a clear standalone exclusivity asset, but each can affect regulatory approval, product consistency and manufacturing cost.

1. Dual-source and regional excipient supply

Pharmaceutical-grade phosphate salts, citric acid and dextrose are available from multiple suppliers. A supplier that can provide consistent particle characteristics, low bioburden, low endotoxin and reliable global documentation can compete for qualified-source status.

The commercial value is higher for suppliers that provide:

• Drug Master File support where appropriate
• compendial and noncompendial impurity profiles
• elemental impurity data
• nitrosamine risk assessments
• extractables and leachables packages
• change-control commitments
• regional regulatory support
• supply continuity for small-volume nasal products

For a low-dose nasal product, variability in raw-material quality can have a disproportionate effect on assay, pH, osmolality and spray performance. A supplier with nasal-product experience can command a premium over a general-purpose excipient vendor.

2. Preservative-free nasal delivery

Trudhesa's preservative-free composition creates an opportunity for manufacturers developing other aqueous nasal products. Preservative-free systems reduce concerns associated with repeated exposure to antimicrobial preservatives, particularly in chronic or recurrent-use products.

The opportunity is strongest in:

• migraine rescue products
• rescue medicines for neurologic disorders
• peptide and protein nasal products
• pediatric nasal products
• allergy products intended for long-term use
• products requiring single-use or low-bioburden presentations

Preservative-free development shifts the burden to container closure integrity, aseptic processing, device design and in-use microbial control. Companies that can combine low-volume aseptic filling with reliable multidose protection have a stronger commercial position than suppliers offering excipients alone.

3. Excipient and device co-development

The formulation cannot be separated commercially from the POD device. A change in viscosity, surface tension, density or osmolality can change plume geometry and deposition. Excipient suppliers can create value by supporting device-development studies rather than selling only raw materials.

Relevant measurements include:

• spray pattern
• plume angle
• droplet and particle-size distribution
• delivered volume
• dose uniformity through container life
• performance after temperature cycling
• performance after orientation and shipping stress
• nasal deposition modeling

A supplier that maintains a formulation-device database for aqueous nasal products could license development packages to specialty pharmaceutical companies. This is more defensible than offering a generic phosphate buffer system.

What formulation patents and intellectual-property barriers affect Trudhesa?

The core intellectual-property risk is likely concentrated in the delivery system, device configuration, manufacturing process, formulation parameters and method of use. Conventional excipients generally provide limited patent protection by themselves.

Formulation patent exposure

A formulation patent could protect:

• DHE concentration
• pH range
• phosphate-to-citrate ratio
• dextrose concentration
• osmolality range
• impurity limits
• stability profile
• preservative-free multidose presentation
• compatibility between formulation and nasal actuator

Even if the individual excipients are old, a defined combination can support patent claims when it produces a measurable performance advantage, such as improved stability, lower irritation or higher upper-nasal deposition.

Device and manufacturing exposure

Trudhesa's commercial differentiation depends heavily on the POD delivery system. Potential barriers include:

• nasal actuator geometry
• mechanical energy or pressure generation
• dose-metering structure
• container-device interface
• priming mechanism
• upper-nasal deposition method
• aseptic filling and assembly
• device performance specifications

A generic applicant may therefore face a more complex path than an ordinary aqueous nasal spray. FDA approval would require an acceptable combination of pharmaceutical equivalence, device performance and bioequivalence under the applicable abbreviated pathway.[3]

When does Trudhesa lose exclusivity?

Trudhesa received FDA approval in September 2021.[4] The applicable regulatory exclusivity period depends on the approval basis, clinical investigations supporting approval and any pediatric exclusivity. Patent expiry depends on the specific issued patent, patent-term adjustment and any patent-term extension.

The commercial exclusivity analysis should separate four categories:

Exclusivity category	Relevance to Trudhesa
New chemical entity exclusivity	DHE is an established active ingredient, so NCE exclusivity is not the primary protection
Clinical investigation exclusivity	May apply to specific approval indications or formulations if statutory requirements are met
Pediatric exclusivity	Could add six months if FDA pediatric obligations qualify
Patent exclusivity	Likely includes device, formulation, method-of-use and manufacturing claims

The approved label and FDA approval records establish the regulatory product profile, but they do not alone establish the complete patent expiry schedule. An Orange Book review should identify listed patents, patent use codes and any later-listed patents. Patent-term calculations should then account for PTA, PTE and terminal disclaimers.

What is the Orange Book status of Trudhesa?

Trudhesa is an FDA-approved prescription drug product, but its commercial risk cannot be assessed from the drug listing alone. The relevant Orange Book questions are:

• Which patents are listed against the product?
• Are the listed patents directed to the formulation, device or method of use?
• What use codes apply?
• Are any patents expired, delisted or subject to a statutory certification?
• Has an ANDA applicant submitted a Paragraph IV certification?
• Is the listed product tied to a specific nasal-device presentation?

An ANDA applicant challenging listed patents would generally evaluate Paragraph IV certification as well as design-around and Section viii strategies. A method-of-use patent may be less obstructive if the applicant can omit the patented indication from its labeling. Device patents and formulation patents are harder to avoid when they cover the product's dose delivery and pharmaceutical composition.

Which companies are challenging Trudhesa?

No specific Paragraph IV challenger or settlement agreement is established in the cited FDA and regulatory sources. The likely competitive set includes:

• generic manufacturers with nasal-spray development capabilities
• specialty pharmaceutical companies pursuing DHE reformulations
• migraine companies developing alternative rescue products
• device companies licensing upper-nasal delivery systems
• contract development and manufacturing organizations with aseptic nasal filling

The most credible challenger would need more than DHE API access. It would need a validated nasal device, reliable dose uniformity, acceptable nasal tolerability and a regulatory strategy that addresses any listed device or formulation patents.

What generic entry risks exist for Trudhesa?

Generic entry could occur through several routes:

Conventional ANDA

An ANDA applicant could seek approval for a product that matches the reference product in active ingredient, strength, dosage form, route and performance. The device may need to be identical or sufficiently equivalent, depending on FDA's product-specific requirements.

505(b)(2) reformulation

A 505(b)(2) applicant could pursue a modified DHE nasal product with:

• a different device
• a different excipient system
• altered dosing
• improved tolerability
• single-dose packaging
• improved stability
• a different nasal deposition profile

This route may support differentiation but can introduce clinical, device and patent disputes.

Non-nasal DHE competition

Injectable or other DHE presentations can compete on speed, flexibility or institutional use. Trudhesa's opportunity is greatest where patients need a noninjectable rescue product with rapid administration and no swallowing requirement.

How strong is the Trudhesa patent estate?

The patent estate should be viewed as potentially stronger around delivery technology than around excipients. The excipients are established pharmaceutical materials and are unlikely to block competitors independently. The commercial strength depends on claim coverage across four layers:

Layer	Relative strategic value
Conventional excipients	Low as standalone exclusivity; important for quality and equivalence
DHE nasal formulation	Moderate if claims cover narrow pH, concentration and stability ranges
POD device	High if claims cover upper-nasal deposition and device mechanics
Manufacturing and assembly	Moderate to high if difficult to reproduce at commercial scale
Method of use	Moderate, depending on indication and label design

A strong estate would require overlapping claims that make a simple device substitution or excipient swap commercially unattractive. A narrow formulation patent without corresponding device coverage would leave more room for a 505(b)(2) competitor.

How does Trudhesa compare with other migraine rescue products?

Product category	Delivery	Excipient opportunity	Main competitive issue
Trudhesa	Upper-nasal DHE spray	Preservative-free aqueous system, device-compatible excipients	Device and formulation replication
Conventional nasal DHE	Anterior nasal spray	Simple aqueous or solution-based systems	Lower differentiation in deposition
Injectable DHE	Intravenous or subcutaneous	Parenteral excipient and container systems	Administration burden
Triptan nasal sprays	Nasal	Solubilizers, buffers, preservatives or tonicity agents	Established generic competition
CGRP antagonists	Oral or other routes	Solid-dose excipients or specialized delivery systems	Convenience and broader patient use

Trudhesa's strongest commercial position is in patients who need nonoral acute therapy but do not want an injection. Its formulation strategy supports that positioning by using a relatively simple aqueous, preservative-free product that is compatible with rapid nasal administration.

What licensing opportunities exist around Trudhesa technology?

Potential licensing transactions fall into three categories:

1. Device licensing: access to upper-nasal delivery technology for other APIs.
2. Formulation licensing: use of preservative-free buffered aqueous systems for nasal products.
3. Combination-product development: co-development of formulation, actuator, filling and regulatory packages.

The most attractive targets are potent drugs where systemic exposure can be achieved through a small nasal volume. Candidate categories include rescue therapies, peptides, CNS drugs and drugs with poor oral absorption.

A licensing package would be more valuable if it includes device tooling, analytical methods, human-factor data, stability protocols, manufacturing instructions and regulatory precedent. Excipient know-how alone would have limited negotiating power because the listed ingredients are broadly available.

What manufacturing and geographic barriers affect commercialization?

Manufacturing barriers include:

• aseptic processing for a preservative-free aqueous product
• low-volume, high-precision filling
• device assembly and dose-metering control
• container closure integrity
• stability testing across global climatic zones
• extractables and leachables qualification
• nasal-spray performance testing
• control of DHE-related impurities

Geographic expansion may require separate regulatory assessments of the device, formulation, manufacturing site and local patent position. The United States is governed by FDA drug and combination-product requirements. Europe and other markets may classify the product and device differently, affecting the approval dossier and conformity assessment pathway.

The strongest international opportunity is a regional partnership with a manufacturer that already operates sterile nasal filling and combination-product assembly. Local API access alone would not remove the principal manufacturing barriers.

Key Takeaways

• Trudhesa uses a simple aqueous excipient system based on phosphate buffers, citric acid, dextrose and water for injection.
• The formulation appears preservative-free, creating opportunities in tolerable, multidose nasal delivery.
• The commercial moat is more likely to be the POD device and formulation-device combination than the individual excipients.
• Excipient suppliers can create value through qualified second sources, analytical support and device-performance collaboration.
• Generic entry could use an ANDA, a 505(b)(2) reformulation or a competing DHE delivery system.
• Patent risk should be analyzed across formulation, device, manufacturing and method-of-use claims.
• The most defensible licensing opportunity is an integrated nasal delivery platform, not the excipient blend alone.
• Manufacturing capability in aseptic filling, device assembly and spray-performance testing is a material barrier to entry.

FAQs About Trudhesa Excipient and Commercial Strategy

Does Trudhesa contain benzalkonium chloride?

The FDA label identifies citric acid monohydrate, dextrose anhydrous, sodium phosphate dibasic anhydrous, sodium phosphate monobasic monohydrate and water for injection. Benzalkonium chloride is not listed as an inactive ingredient.[1]

Can a generic manufacturer replace the Trudhesa excipients?

A 505(b)(2) applicant may pursue a modified excipient system, but it would need to address pharmaceutical performance, nasal tolerability, stability, device compatibility and bioequivalence. An ANDA strategy generally faces tighter equivalence requirements.

Is the Trudhesa formulation protected by the excipients themselves?

The individual excipients are established materials. Patent value would more likely arise from defined concentrations, pH, stability limits, device interaction or manufacturing controls.

What is the best excipient opportunity in nasal migraine products?

The strongest opportunity is a preservative-free, low-volume aqueous system supported by validated aseptic filling, multidose microbial protection and reproducible spray performance.

Can Trudhesa's nasal device be licensed for other drugs?

A nasal delivery platform can have value beyond DHE if it can reproducibly deliver other potent APIs within suitable volume, viscosity, pH and stability ranges. The commercial value depends on device rights, manufacturing know-how and regulatory transferability.

References

1. U.S. Food and Drug Administration. (2021). Trudhesa (dihydroergotamine mesylate) nasal spray prescribing information. FDA.
2. Impel NeuroPharma, Inc. (2021). Trudhesa product and delivery-technology information.
3. U.S. Food and Drug Administration. (2020). Product-specific guidance for industry: Dihydroergotamine mesylate nasal spray. FDA.
4. U.S. Food and Drug Administration. (2021). FDA approves Trudhesa for acute treatment of migraine. FDA.